Avadel Pharmaceuticals (AVDL)
(Delayed Data from NSDQ)
$13.24 USD
+0.04 (0.30%)
Updated Oct 16, 2024 04:00 PM ET
After-Market: $13.24 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth D Momentum D VGM
Balance Sheet
Fiscal Year End for Avadel Pharmaceuticals PLC falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 105 | 97 | 157 | 221 | 64 |
Receivables | 12 | 0 | 0 | 0 | 8 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 10 | 0 | 0 | 0 | 4 |
Other Current Assets | 7 | 4 | 35 | 42 | 6 |
Total Current Assets | 134 | 101 | 192 | 263 | 82 |
Net Property & Equipment | 1 | 1 | 0 | 0 | 1 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 17 | 17 | 17 | 17 | 19 |
Deposits & Other Assets | 10 | 13 | 35 | 28 | 46 |
Total Assets | 165 | 133 | 247 | 312 | 151 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 11 | 8 | 8 | 3 | 6 |
Current Portion Long-Term Debt | 0 | 38 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 24 | 7 | 7 | 7 | 20 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 2 | 5 | 5 | 9 |
Total Current Liabilities | 37 | 56 | 21 | 15 | 36 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 92 | 142 | 128 | 122 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 38 | 6 | 4 | 4 | 21 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 77 | 154 | 169 | 149 | 181 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 1 | 1 | 1 | 1 | 0 |
Capital Surplus | 855 | 590 | 549 | 567 | 434 |
Retained Earnings | -746 | -585 | -448 | -384 | -391 |
Other Equity | -23 | -26 | -24 | -21 | -23 |
Treasury Stock | 0 | 0 | 0 | 0 | 50 |
Total Shareholder's Equity | 88 | -21 | 78 | 162 | -29 |
Total Liabilities & Shareholder's Equity | 165 | 133 | 247 | 312 | 151 |
Total Common Equity | 88 | -21 | 78 | 162 | -29 |
Shares Outstanding | 89.80 | 61.70 | 58.60 | 58.40 | 37.40 |
Book Value Per Share | 0.98 | -0.34 | 1.33 | 2.78 | -0.78 |
Fiscal Year End for Avadel Pharmaceuticals PLC falls in the month of December.
All items in Millions except Per Share data.
9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 71 | 89 | 105 | 153 |
Receivables | NA | 33 | 23 | 12 | 6 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 13 | 12 | 10 | 5 |
Other Current Assets | NA | 8 | 13 | 7 | 8 |
Total Current Assets | NA | 126 | 136 | 134 | 172 |
Net Property & Equipment | NA | 0 | 1 | 1 | 1 |
Investments & Advances | NA | 0 | 0 | 0 | 0 |
Other Non-Current Assets | NA | 0 | 0 | 0 | 0 |
Deferred Charges | NA | 0 | 0 | 0 | 0 |
Intangibles | NA | 17 | 17 | 17 | 17 |
Deposits & Other Assets | NA | 12 | 12 | 10 | 11 |
Total Assets | NA | 158 | 168 | 165 | 203 |
Liabilities & Shareholders Equity | 9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | 0 |
Accounts Payable | NA | 10 | 19 | 11 | 13 |
Current Portion Long-Term Debt | NA | 0 | 0 | 0 | 21 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | NA | 34 | 28 | 24 | 18 |
Income Taxes Payable | NA | 0 | 0 | 0 | 0 |
Other Current Liabilities | NA | 0 | 0 | 0 | 1 |
Total Current Liabilities | NA | 45 | 48 | 37 | 54 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 0 | 0 | 0 | 0 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 40 | 38 | 37 | |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 87 | 90 | 77 | 93 |
Shareholders Equity | 9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | NA | 1 | 1 | 1 | 1 |
Capital Surplus | NA | 880 | 874 | 855 | 852 |
Retained Earnings | NA | -787 | -773 | -746 | -717 |
Other Equity | NA | -24 | -24 | -23 | -26 |
Treasury Stock | NA | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | NA | 70 | 78 | 88 | 110 |
Total Liabilities & Shareholder's Equity | NA | 158 | 168 | 165 | 203 |
Total Common Equity | 0 | 70 | 78 | 88 | 110 |
Shares Outstanding | 96.20 | 96.20 | 96.10 | 89.80 | 89.40 |
Book Value Per Share | 0.00 | 0.73 | 0.82 | 0.98 | 1.23 |